NASDAQ NMS - GLOBAL MARKET · ANTX
+3.06% · +$0.1500 · Vol 671.0K
Market closed · last close 4:00 PM ET · price as of 16:14:04 ET
AN2 Therapeutics Inc

AN2 Therapeutics Inc

Pharmaceuticals
$5.05
Card
Relationship Map

Follow $ANTX

One email when a member of Congress discloses a trade in it, with the official filing receipt linked.

Free. No account. Unsubscribe in one click.

Follow $ANTX by email

Veridion Score

BETAMEDIUM CONF · 6 of 6 factors measuredMethodology
ANTX
AN2 Therapeutics Inc
Fri Sep 18 · last completed session · Markets closed · resumes Mon 9:30 ET
Middle range

Highest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

58/ 100
Veridion Score
Middle range · MEDIUM confidence · 6 of 6 factors measured
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: MEDIUM · 6 of 6 factors measured · Fri Sep 18 · last completed session · Markets closed · resumes Mon 9:30 ET
Share on X →
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is ANTX moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading ANTX catalysts
About AN2 Therapeutics Inc
PHARMACEUTICAL PREPARATIONS
Listed since
2022
Employees
21
Country
US

AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology. Product candidate AN2-502998 Epetraborole.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$4.89
Day high
$5.15
Day low
$4.80
Previous close
$4.90
52W high
$6.28
-19.59% from high
52W low
$1.03
77% of range
Market cap
$190.6M
EPS
$-0.9900
Beta
0.79
Shares out
37.7M
Volume
671K
3.00× rel vol
Avg volume
223.8K
VWAP
$5.03
Price history computed in-house
1W
-6.65%
1M
-13.08%
3M
-6.48%
1Y
+282.58%
YTD
+342.98%
SMA 50 $5.44 · below
SMA 200 $3.58 · above
52W position 77%

ANTX overview

Veridion Score
58
Registered · 2026-09-18
6 of 6 factors measured
Latest receipt rows
0
No recent disclosure on file.
13F holders
None on file

Related filings and maps

Relationship mapTrace receipt-backed holders and filings around ANTX.Congress trackerSearch the public STOCK Act disclosure ledger.MethodologyReview score inputs, coverage rules, and limitations.
Loading financial statements
Loading ANTX Form 4 filings
Public disclosures

Congress activity in ANTX

Congress trackerOpen ticker disclosure ledger →

No receipt-qualified Congressional disclosure is present for ANTX in the cached public ledger.

Federal contracts

ANTX contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for ANTX in this window.
Lobbying spend

ANTX lobbying filings, year to date.

Registered lobbying filings matched to AN2 Therapeutics Inc.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for ANTX in this window.
Loading news for ANTX
Analyst ratings
Sovereign unlock shows live analyst consensus for ANTX.
Options
Sovereign unlock shows live options positioning for ANTX.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.